Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G2CY
|
|||
| Former ID |
DNC009204
|
|||
| Drug Name |
(+/-)-3-allylazetidin-2-one
|
|||
| Synonyms |
3-(2'-propenyl)-2-azetidinone; 1058693-04-1; allyl-beta-lactam; CHEMBL447982
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H9NO
|
|||
| Canonical SMILES |
C=CCC1CNC1=O
|
|||
| InChI |
1S/C6H9NO/c1-2-3-5-4-7-6(5)8/h2,5H,1,3-4H2,(H,7,8)
|
|||
| InChIKey |
XWLCLNCCEDQVSS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.